US 12,419,870 B2
Compositions and methods for immune cell modulation in adoptive immunotherapies
Jonathan Rosen, San Diego, CA (US); Betsy Rezner, San Diego, CA (US); Bahram Valamehr, San Diego, CA (US); Ryan Bjordahl, San Diego, CA (US); Eigen Peralta, San Diego, CA (US); and Ian Hardy, San Diego, CA (US)
Assigned to Fate Therapeutics, Inc., San Diego, CA (US)
Filed by Fate Therapeutics, Inc., San Diego, CA (US)
Filed on Jul. 8, 2022, as Appl. No. 17/861,042.
Application 17/861,042 is a continuation of application No. 16/071,460, granted, now 11,413,309, previously published as PCT/US2017/014449, filed on Jan. 20, 2017.
Claims priority of provisional application 62/402,883, filed on Sep. 30, 2016.
Claims priority of provisional application 62/281,064, filed on Jan. 20, 2016.
Prior Publication US 2022/0401487 A1, Dec. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/436 (2006.01); A61K 35/28 (2015.01); A61K 35/545 (2015.01); A61K 38/09 (2006.01); A61K 38/14 (2006.01); A61K 38/21 (2006.01); A61K 38/50 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 31/436 (2013.01) [A61K 35/28 (2013.01); A61K 35/545 (2013.01); A61K 38/09 (2013.01); A61K 38/14 (2013.01); A61K 38/212 (2013.01); A61K 38/50 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); A61K 45/06 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C12N 2510/00 (2013.01); Y02A 50/30 (2018.01)] 16 Claims
OG exemplary drawing
 
1. A composition, wherein the composition is a culture medium comprising a combination,
wherein the combination comprises (a) a mammalian target of rapamycin (mTOR) inhibitor, and (b) dimethyl prostaglandin E2 (dmPGE2) or an analogue or derivative thereof; and
wherein the combination is present in an amount effective to modulate a population of T cells to (a) reduce expression of one or more T cell exhaustion markers, or (b) increase mitochondrial spare respiratory capacity, in comparison to a corresponding population of T cells that are not modulated with the combination.